TCBP Announces Dosing of 6th Patient in ACHIEVE Study in Patients with Acute Myeloid Leukemia 5 patients treated in "safety cohort" showed no drug related Serious Adverse Events Restart of trial after amendment approved by MHRA to increase dose level EDINBURGH, Scotland , July 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on July 16, the sixth patient in ACHIEVE (UK) was treated. This is the first patient treated with a higher dose of TCB-008 post the amendment approved by the MHRA on Feb 22, 2024.
TC BioPharm Reschedules 2024 AGM for July TC Biopharm (Holdings) Plc Sponsored ADR (TCBP) has released an update. TC BioPharm (Holdings) Plc has rescheduled its 2024 Annual General Meeting …
TC Biopharm Board Members Resign Suddenly The latest announcement is out from TC Biopharm (Holdings) Plc Sponsored ADR (TCBP). Mark Bonyhadi and Edward Niemzyck have abruptly resigned from …
TCBP Announces Launch of Compassionate Use Program for TCB008 The Company's lead therapeutic will be available through a newly opened compassionate use program EDINBURGH, Scotland , May 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company's lead therapeutic TCB008 will be available to patients via a newly launched compassionate use program in the UK. Compassionate use refers to the prescription of unlicensed medicinal products to treat a patient in instances where their individual clinical needs cannot be met with the available licensed treatments.
TC BioPharm secures $3.1 million from warrant exercise https://www.investing.com/news/company-news/tc-biopharm-secures-31-million-from-warrant-exercise-93CH-3421618
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds EDINBURGH, Scotland , May 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company's American Depositary Shares (the "ADSs") originally issued in December 2023 with an exercise price of £1.5814 per ADS and a term of five years. Each ADS represents twenty ordinary shares of the Company.
Why Is TC Biopharm (TCBP) Stock Up 51% Today? TC BioPharm (NASDAQ: TCBP ) stock is rocketing higher on Monday after the clinical-stage biopharmaceutical company announced a major deal to acquire another company. According to a press release from TC BioPharm, it intends to acquire a private biotechnology company developing Chimeric Antigen Receptor T-cell (CAR-T) therapies.
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies Acquisition target has established proof of concept data demonstrating the therapeutic potential for the treatment of multiple solid tumors EDINBURGH, Scotland , May 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors. This agreement is the second such agreement in as many months shows TCBP's commitment to its M&A strategy aimed at expanding its therapeutic platform.